Stage IIIA Breast Cancer Clinical Trial
Official title:
Active Living After Cancer: Building a Physical Activity Intervention Into Clinical Care for Breast and Colorectal Cancer Survivors in Wisconsin
This randomized pilot clinical trial studies how well survivorship care plan works in promoting technology-based physical activity in breast or colorectal cancer survivors in Wisconsin. A survivorship care plan may help doctors to better understand how they can help people who have been diagnosed with cancer to become more physically active. It is not yet known whether a standardized cancer survivor plan used as part of routine care or a technology-based physical activity intervention is better in promoting physical activity in breast or colorectal cancer survivors.
PRIMARY OBJECTIVES:
I. Establish the feasibility of enrolling breast and colorectal cancer survivors along with a
co-survivor into a randomized physical activity promotion trial.
II. Determine the short-term effect of an enhanced survivorship care plan (SCP) compared to
the standard SCP on objectively-measured physical activity among survivors and co-survivors.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I (Enhanced SCP): Participants receive an enhanced SCP, comprised of a personalized
document that summarizes treatment and follow up recommendations, including basic physical
activity guidance. Participants also receive a copy of the United States Department of
Agriculture (USDA) Dietary Guidelines for Americans, as well as standardized emails with
wellness tips and information on stress management provided from the American Heart
Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks. Specific topics in emails
include "positive self-talk", "daily relaxation breathing techniques", "better sleep", and
"ways to find pleasure". Participants also wear a Fitbit web-integrated physical activity
tracker daily for 12 weeks and receive email feedback specific to each participant based on a
series of factors, including their Fitbit data, Emails may provide encouragement, such as
"keep up the good work", and/or very specific instructions regarding compliance with the
intervention, goals for meeting physical activity goals, potential strategies to
increase/maintain levels of physical activity, etc., and technical or how-to support
including how to use the device and website, or questions about goal-setting.
ARM II (Control): Participants receive a standard SCP, comprised of a personalized document
that summarizes treatment and follow up recommendations, including basic physical activity
guidance. Participants also receive a copy of the USDA Dietary Guidelines for Americans, as
well as standardized emails with wellness tips and information on stress management provided
from the American Heart Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks.
Specific topics in emails include "positive self-talk", "daily relaxation breathing
techniques", "better sleep", and "ways to find pleasure".
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Terminated |
NCT02454777 -
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
|
N/A | |
Completed |
NCT03061175 -
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
|
N/A | |
Completed |
NCT01959490 -
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Terminated |
NCT01368263 -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT01928186 -
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
|
N/A | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00070252 -
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT01478477 -
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
|
N/A | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00416715 -
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
|
Phase 2 |